Keywords: Multiple Sclerosis, Multiple Sclerosis, Myelin, iron
Motivation: Noninvasive tools for monitoring the changes in tissue during treatment is an important clinical need. In Multiple Sclerosis (MS), estimation of iron and myelin content is essential.
Goal(s): This study aims to demonstrate the potential of a newly developed technique for myelin and iron change detection during treatment from gradient-echo data.
Approach: Data from 29 MS patient were retrospectively collected over a period of time that covers the treatment start and all data were processed to estimate iron and myelin biomarkers.
Results: Statistical analyses showed that the Ocrelizumab treatment caused overall iron decrease and remyelination.
Impact: Treatment efforts in Multiple Sclerosis includes medications that suppress acute inflammation. Therefore, the noninvasive quantification of the effect of treatment on the iron change and remyelination carries significant importance. Here, a novel gradient-echo based approach is tested for this purpose.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords